Hansa Biopharma stock
HNSA.STSTOHansa Biopharma AB (publ), HealthcareISIN SE0002148817
47Score 47 out of 100, Weak
Price and trend
85 / 100
Price history
+74% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 34% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is at its 52-week high. Largest decline in 19 years: 94% (October 2018 to October 2023).
Chart figures for advanced users
- SMA 50$3.79
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.49
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.51
- The lowest closing price of the last twelve months.
- Resistance$4.70
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Hansa Biopharma AB (publ) belongs to the Biotechnology industry (Sweden) and, with a market value of $474.2M, is number 251 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $22.38M (up 29.7% year on year) and a loss of $53.78M.
- For fiscal 2026, analysts expect on average revenue of $36.47M (up 63%) and adjusted earnings per share of −$0.04.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 424 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 105.3% a year since 2020, Biotechnology median 19.7%.Growth 70
Weaknesses
- DilutionShare count up 93% since 2020.Capital allocation 18
- Loss-makingLoss of $77.54M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$55M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 29.7% on the prior year. Revenue has grown strongly since 2008, at around 57% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 62%, operating −234%, net −240%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 11 Nov 2026EPS reported −$0.17 (expected −$0.14)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 139.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.04−139.8%
- Revenue
- $36.47M−22.5%
- Earnings per share
- −$0.57+10.9%
- Revenue
- $35.76M+2.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Hansa Biopharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Relmada TherapeuticsRLMD $472.55M38
- Oculis HoldingOCS $469.78M30
- BlossomHill TherapeuticsBLSM $468.79M43
- CytomX TherapeuticsCTMX $464.35M31
- Assembly BiosciencesASMB $455.47M33
- ArvinasARVN $452.5M37
- AgenusAGEN $452.32M49
- Gyre TherapeuticsGYRE $451.7M35
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.